TP53 and neoplasm: Although p53 gene therapy drugs are still in clinical trials, and very few drugs have been marketed so far, the combination of adenovirus and radiotherapy for tumor treatment has the following advantages: i) reversing the resistance of tumor cells to radiotherapy; ii) synergistic effects to improve the efficacy; iii) killing residual tumor cells, prolonging disease-free survival, and improving the survival rate; iv) reducing the toxic side effects of radiotherapy and improving the quality of life by allowing for less intensive treatment.70